drugset / Trial / NCT02947581

Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)

NCT02947581

Phase 3 Terminated 107 enrolled Universidad Peruana Cayetano Heredia
RandomizedParallel-groupDouble-blindTreatment

Summary

Taenia solium neurocysticercosis (NCC) is a parasitic infection causing much neurological disease in most of the world. When parasites locate in the cavities around the brain (subarachnoid NCC, SANCC), it becomes an aggressive, progressive and frequently lethal presentation. Current treatment regimens for SANCC have quite limited efficacy. The investigators propose to compare the current standard of care (a single antiparasitic drug, albendazole) with a combined regimen using two antiparasitic drugs simultaneously by adding praziquantel. The trial will enrol 164 patients in four centers, two in Peru, one in Ecuador, and one in Brasil.

Timeline

Start
2016-11-14
Primary completion
2020-08-21
Completion
2021-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Praziquantel Small molecule 50 mg/kg
Comparator Albendazole Small molecule 15 mg/kg

Indications